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Introduction
Multiple sclerosis (MS) is most often diagnosed between 
the ages of 20-40, the age at which many people may be 
thinking of starting or extending their family. Recent analy-
sis of the 3rd edition of the Atlas of MS as an open-source 
global compendium of data regarding the epidemiology of 
MS showed that globally females are twice as likely to have 
MS as males and this is consistent with both prior editions 
of the Atlas. However, the ratio of women to men is as high 
as 4:1 in some countries, and in others this ratio has doubled 
since 2013 [1]. This disproportional increase of MS inci-
dence in females, particularly notable in the Middle East, 
is explained by some investigators as a result of improved 
diagnostic methods and a better access to MRI [2, 3]. 
In a survey of 5949 patients, registered in the NAR-
COMS (North American Research Committee on Multiple 
Sclerosis) database, 79% of patients did not become preg-
nant after a diagnosis of MS. In 34.5% of these patients, the 
choice concerned MS-related issues [4]. A survey on 271 
female patients with MS in Switzerland undertaken to help 
understand the effects of family planning on their treatment 
decisions revealed their concerns about: disease course dur-
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Abstract
Background: Multiple sclerosis (MS) is a disease that affects young people of reproductive age (20-40 years old), predominantly women. Therefore, almost 
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and during pregnancy suggests no evidence of increase in the rate of congenital anomalies or spontaneous abortions. For women with persistent high 
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ing pregnancy (44%), disease course after pregnancy (61%), 
the health of the unborn child (47%), possibility for breast-
feeding (21%), taking care of the child after birth (45%), the 
availability of MS therapy options (35%) [5]. It is important 
to provide a framework to discuss concerns regarding preg-
nancy and MS, as well as the uncertainty about the course of 
disease during pregnancy, postpartum and in the long-term.
Management of women with MS is a complex task that 
should cover pre-pregnancy guidance, care during pregnan-
cy, delivery and anesthetic options, postpartum and specific 
advice concerning currently approved disease-modifying 
drugs [6]. 
Despite the growing number of therapeutic options for 
individualized treatment, it is still a question how to manage 
MS in women who become pregnant while taking disease-
modifying drugs or want to become pregnant after start-
ing this treatment. It is therefore important to proactively 
discuss family planning and pregnancy, especially when 
considering disease-modifying treatments. As the complex-
ity and spectrum of available disease-modifying drugs in-
crease, in many countries MS pregnancy data is being ga-
thered in nationwide registries.
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This literature review that includes data from national 
registries demonstrates the modern approach to the man-
agement of women with MS with reproductive potential 
depending on the disease activity and the stage of family 
planning.
Discussion
Today it is known that MS is not a hereditary disease, 
and does not significantly affect the ability of conception, 
and the likelihood of adverse pregnancy outcomes such as 
the risk of spontaneous abortions, stillbirth, cesarean deliv-
ery, premature birth, or birth defects [4]. However, preg-
nancy planning should not coincide with time of diagnosis, 
to allow for evaluation of disease activity and course. It is 
recommended to ensure disease control before pregnancy, 
depending on disease activity with stabilization for at least 1 
year before pregnancy. Proactive counselling and formula-
tion of a pregnancy and disease management plan with at 
least annual revision may help to avoid the situation when 
following discussion with their health care practitioner 
(HCP), women with MS defer treatment because they wish 
to have children in the future [6-8].
Women with MS should follow standard advice for all 
pregnant women: ensure good sleep, hygiene, and diet, 
avoid alcohol and smoking, take recommended routine pre-
natal supplements including folic acid [4, 6, 7]. Along with 
the absence of a significant impact of MS on child health, 
women with MS considering pregnancy should be coun-
seled upon the unpredictable course of MS, the effect of MS 
on the course of pregnancy, on how the pregnancy may af-
fect disease. The potential teratogenic risk associated with 
disease modifying drugs (DMDs) and the increased risk of 
vitamin D deficiency associated with MS should also be dis-
cussed within pre-pregnancy consultation [6, 9, 10]. 
Although MS has no significant impact on the ability of 
women to conceive, about 10% of all women have difficul-
ties getting or staying pregnant and may choose to use as-
sisted reproductive technology (ART) [4]. In most studies, 
women stopped taking DMDs prior to initiating ART, leav-
ing them at a higher risk of relapse. Additionally patients 
with MS may experience an increase in relapse rate follow-
ing the use of ART, which may be the result of stress and 
hormone alterations associated with ART. Distress is also 
associated with in-vitro fertilization failure [7, 11].
While women are pregnant, they may experience fewer 
MS relapses, especially in the third trimester [12-14]. How-
ever, in patients with highly active disease, pregnancy may 
not be sufficient to control disease activity [6]. About 25% of 
women experience a relapse within 40 weeks of pregnancy 
and nearly 30% within the first 3 months after giving birth. 
These data are mainly derived from studies involving un-
treated women during and after pregnancy. A risk factor for 
increased disease activity after childbirth is relapse during 
the year before and during pregnancy [15]. It is important 
to note that pregnancy has no effect on the progression of 
disability in MS [16]. In this regard, it is important to con-
tinue therapy, but most DMDs are contraindicated during 
pregnancy (tab. 1).
Pregnancy may often complicate the diagnosis of new 
disease activity. Clinical presentation of MS can be similar 
to common pregnancy-related symptoms, which makes it 
difficult to attribute any symptoms to the disease process 
if they develop during an established pregnancy [17]. Al-
though pregnant women may experience fewer relapses, 
pregnancy may exacerbate other MS symptoms. One of the 
most common pregnancy-related symptoms similar to pre-
sentation of MS is fatigue. Pregnant women may find that 
they do not sleep well, and maternal iron deficiency may 
also lead to anaemia and fatigue. Current evidence suggests 
that women with MS have a higher risk of anaemia during 
pregnancy when compared with healthy individuals [17]. In 
some countries (in the U.S.) amantadine is used as the only 
approved treatment for fatigue, but there are no adequate 
studies in pregnant women regarding the use of this medi-
cation. In pregnancy, increasing weight may diminish mo-
bility which can mimic reduced mobility in MS. Spasticity 
and gait abnormalities may worsen with pregnancy. Pres-
sure from the uterus on the bladder may increase frequency 
of urination resembling bladder and bowel dysfunction. 
Vision changes due to pregnancy-induced hypertension 
as well may seem to the patient as a manifestation of MS, 
therefore other possible causes of vision problems should 
also be excluded.
Indicators of new onset of MS symptoms may include 
sensory changes, paralysis, muscle weakness or spasm, cog-
nitive changes. Pregnant women with MS who notice wors-
ening of pre-existing conditions or a new onset of distinct 
MS-related symptoms should undergo neurological exami-
nation. The neurological condition of all pregnant patients 
with MS should be ideally checked every 3 months includ-
ing screening for depression and anxiety given that many 
women with MS may experience a higher incidence of de-
pression during pregnancy [17]. Existing comorbidities can 
also contribute to general deterioration. Urinary tract infec-
tions may be more frequent in pregnant women with MS 
when compared with pregnant healthy controls [6, 17]. To 
date there is a current lack of data on the safety of treatments 
for some comorbidities in pregnant women. Regarding 
treatment of severe relapses during pregnancy warranting 
treatment published literature reports on corticosteroids, 
which may be considered depending on corticosteroid type, 
period of pregnancy, and duration of treatment and dosage. 
During the second and third trimesters, short courses (3–5 
days) of prednisolone or methylprednisolone may be con-
sidered. Corticosteroid administration should be avoided 
during the first trimester of pregnancy due to the potential, 
but rare, risk of teratogenic effects (e.g. cleft palate). Plasma 
exchange may be taken into account for severe relapses that 
are not responsive to corticosteroid treatment [6, 7, 18].
For women who experience relapse warranting imaging, 
there are no conclusive data to show that MRI exposure up 
to 3T is associated with foetal harm, but gadolinium should 
be avoided [6, 7, 18]. Regarding additional foetal scans in 
women with MS, Association of British Neurologists (ABN) 
guidelines state that it is not required [6].
Today it is known that after childbirth, the level of hor-
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mones and cytokines returns to normal and the activity of 
the disease increases. This gradual normalization decreases 
the immunosuppressive effect of pregnancy and leads to an 
increase in MS activity. Additionally, this can also be facili-
tated by the stressful effect of childbirth itself and the in-
creasing stress in a woman associated with childcare.
Global trends show that the waiting time before resum-
ing therapy after childbirth can last up to 100 days, which 
is often associated with the inability to use DMD during 
breastfeeding, although therapy is extremely important to 
reduce disease activity and slow the progression of disabili-
ty. According to Hellwig K. et al., 2012 about 30% of women 
experience a relapse within the first 3 months after giving 
birth. This data was obtained from patients who were not 
taking DMDs [15].
Some of the implications of stopping DMDs use which 
must be considered are: loss of disease-control benefits af-
ter stopping DMDs requiring continuous administration, 
potential rebound disease, further monitoring, and elimi-
nation periods of up to 48 months for some medications. 
Recommended preconception washout periods for DMDs 
vary greatly (tab. 1).
International American Academy of Neurology (AAN) 
2018 and ABN 2019 guidelines state that DMD choice 
may be influenced by plans for pregnancy and during pre-
pregnancy counselling, HCPs should consider the safety of 
all drug treatments during pregnancy when prescribing to 
women of childbearing age [6, 32].
According to ECTRIMS/EAN 2018 guidelines the use 
of interferon beta or glatiramer acetate until pregnancy is 
confirmed may be considered for women with a high risk of 
disease re-activation; treatment continuation may be con-
sidered in specific cases. In women with persistent high dis-
ease activity who do not wish to delay pregnancy, treatment 
with some DMDs during pregnancy could be an option af-
ter discussion of the potential implications [33].
Based on available data, interferon beta and glatiramer 
acetate appear to be most suitable for use up until the time 
of confirmed pregnancy. However, a systematic review con-
cluded that further research was necessary for glatiramer 
acetate as studies were small. Natalizumab is a large mol-
ecule that is unlikely to cross the placental barrier to any 
great extent during early pregnancy. If natalizumab is ad-
ministered in the last quarter of pregnancy, concentrations 
may be higher in infants than in mothers which can result in 
reversible hematological abnormalities such as thrombocy-
topenia and anemia. Natalizumab must be discontinued at 
a maximum of 3 months prior to pregnancy. After consid-
eration of the individual risk-benefit, natalizumab may be 
given until pregnancy is confirmed or, in rare cases, the ben-
efit of continuing natalizumab during the entire pregnancy 
may outweigh the risk of recurring severe disease activity 
but only after careful risk-benefit consideration. It is recom-
mended that a pediatrician be in attendance during delivery 
and that blood cell count, liver enzymes, haptoglobin and 
bilirubin be controlled in the newborn [16].
To date, emerging data continue to change family plan-
ning for people with MS given the increased identification 
of long-term developmental effects on children exposed to 
DMDs.
Data from global registries demonstrates that there is no 
evidence of an adverse effect of interferon beta-1a on preg-
nancy outcomes or on the frequency of live births of children 
with congenital abnormalities. Both indicators, as well as the 
body weight of newborns, are in accordance with indicators 
in the general population. Based on over 1000 pregnancy 
outcomes, obtained from registers and post-registration ob-
servations, EMA approved respective changes in label. 
The European Interferon-beta Pregnancy Registry is a 
prospective collection of pregnancy data from interferon 
beta-treated women from 31 European countries. Between 
2009 and 2017, the registry collected 948 pregnancy reports 
with a known pregnancy outcome. This is one of the larg-
est prospective cohort studies conducted to date, providing 
data on pregnancy outcomes in women with MS who re-
ceived interferon beta. Of the known outcomes, 794 were 
live births. Overall, 82.0% (777/948) of pregnancies resulted 
in live birth without congenital anomaly. When comparing 
IFN-beta-exposed pregnancies with the general population, 
the prevalence of spontaneous abortions (10.7% vs 10–21%) 
and congenital anomalies in live births (2.1% vs 2.1–4.1%) 
were found to be within reported ranges. The data gathered 
from these pregnancy cases suggest no evidence that IFN-
beta exposure before conception and/or during pregnancy 
adversely increases the rate of congenital anomalies or 
spontaneous abortions [34].
The German MS Pregnancy Registry is a nationwide 
collection of data on pregnancy outcomes for women diag-
nosed with relapsing-remitting MS, conducted from 2008 to 
2013. It was shown that the proportion of live births, aver-
age body weight and length at birth, as well as the time of 
onset of labor in patients with MS who took interferon beta 
(n = 251) were comparable to those in the group untreated 
with DMDs (n = 194) [35].
The Scandinavian registry includes data on pregnancies 
in Finland and Sweden from 1996 to 2014 (n = 3054). Ac-
cording to its results, there was no evidence of adverse preg-
nancy outcomes in connection with the use of interferon 
beta. The incidence of spontaneous abortions is comparable 
in the interferon beta-1a cohort and in the cohort without 
DMD treatment (8.1% vs 11.1% respectively). The propor-
tion of cases of ectopic pregnancy in women who received 
interferon beta-1a was 1.6% vs 2.9% in the group without 
DMD treatment. The weight of the live births without con-
genital abnormalities in the groups receiving and not receiv-
ing therapy was similar [36].
The database analysis by Sandberg-Wollheim M. et al., 
2011 presents prospective and retrospective reports on the 
safety of Rebif (interferon beta 1-a), including post-market 
observational data and isolated reports from clinical trials. 
Prospective data (n = 425) indicate no increase in the in-
cidence of spontaneous abortions in women who received 
Rebif (11.5%) compared to the general population (up to 
20%) [37]. 
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Table 1. Recommended contraception period (months after last dose) use during pregnancy and breastfeeding 








mended for 4 months follow-
ing each course of treatment
Alemtuzumab may cross the placental barrier and thus 
be potentially dangerous to the fetus. Animal studies 
have demonstrated reproductive toxicity. It is not known 
whether alemtuzumab can harm the fetus when given 
to pregnant women or whether it can alter reproductive 
capacity. Alemtuzumab should be administered during 
pregnancy only if the potential benefit justifies the po-
tential risk to the fetus.
Breast-feeding should be sus-
pended during each course of 
treatment and for 4 months fol-





mended for 6 months after last 
dose, ensuring that  a barrier 
method is included during 
treatment and 1 month after 
last dose
Animal studies have shown reproductive toxicity. Cladrib-
ine is contraindicated in pregnant women
Breast-feeding should be discon-
tinued during treatment with 




None given Animal studies have shown reproductive toxicity. Di-
methyl fumarate is not recommended during pregnancy 
and in women of childbearing potential not using ap-
propriate contraception
A decision must be made wheth-
er to discontinue breast-feeding 




None given Studies in animals have not shown reproductive toxicity. 
Current data on the use of glatiramer acetate 20-40 mg/
ml in pregnant women indicate no malformative or feto/
neonatal toxicity. To date, no relevant epidemiologi-
cal data are available. As a precautionary measure, it is 
preferable to avoid the use of glatiramer acetate during 
pregnancy unless the benefit to the mother outweighs 
the risk to the foetus.
A decision must be made 
whether to discontinue breast-
feeding or to discontinue/abstain 
from glatiramer acetate therapy 
taking into account the benefit 
of breast-feeding for the child 
and the benefit of therapy for the 
woman.
Fingolimod [23] Contraception use recom-
mended for at least 2 months 
after last dose
Based on human experience, post-marketing data sug-
gest that the use of fingolimod is associated with a 2-fold 
increased risk of major congenital malformations when 
administered during pregnancy compared with the rate 
observed in the general population (2-3%; EUROCAT). 
Consequently, fingolimod is contraindicated during 
pregnancy. 
Due to the potential for serious 
adverse reactions to fingoli-
mod in nursing infants, women 




None given A considerable amount of data (more than 1000 preg-
nancy outcomes) from registries and post-marketing ex-
perience does not show a higher risk of major congenital 
anomalies after exposure to interferon beta during pre-
conception or the first trimester of pregnancy. However, 
the extent of exposure during the first trimester is ques-
tionable, given that data were gathered when interferon 
beta use was contraindicated during pregnancy, and 
treatment was presumably stopped when pregnancy 
was detected and/or confirmed. Evidence regarding 
exposure during the second and third trimester is very 
limited.
Based on animal studies, there is a possibly higher risk for 
spontaneous abortion. The risk of spontaneous abor-
tions in pregnant women exposed to interferon beta 
cannot be appropriately evaluated based on the data 
that are available, but the evidence does not suggest an 
increased risk thus far.
If clinically needed, the use of interferon beta may be 
considered during pregnancy.
Limited information available on 
the transfer of interferon beta-1a 
into breast milk, together with 
the chemical/physiological 
characteristics of interferon beta, 
suggests that levels of interferon 
beta-1a excreted in human milk 
are negligible. No harmful effects 
on the breastfed newborn/infant 
are anticipated.
Interferon beta can be used dur-
ing breast-feeding.
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There is limited information on the penetration of inter-
feron beta-1a into breast milk. It is known that interferon 
beta-1a is not able to easily get into breast milk, since it is a 
large polar molecule (22500 Da) closely bound up with T-




mended for at least 4 months 
for women and at least 
6 months for men after last 
dose
There are very limited data on the use of mitoxantrone 
in pregnant women. Mitoxantrone was not teratogenic 
in animal studies at doses below human exposure but 
caused reproductive toxicity. Mitoxantrone is considered 
a potential human teratogen because of its mechanism 
of action and the developmental effects demonstrated 
by related agents. For this reason, the use of mitoxan-
trone to treat MS is contraindicated for pregnant women. 
Because of the potential for seri-
ous adverse reactions in infants 
from mitoxantrone, breast-feed-
ing is contraindicated and must 




None given If a woman becomes pregnant while taking natalizumab, 
discontinuation of treatment should be considered. A 
benefit-risk evaluation of the use of natalizumab during 
pregnancy should take into account the patient’s clinical 
condition and the possible return of disease activity after 
stopping the treatment.
Animal studies have demonstrated reproductive toxicity. 
Data from clinical trials, a prospective pregnancy registry, 
post-marketing cases and available literature do not 
suggest an effect of this medicinal product exposure on 
pregnancy outcomes.
The completed prospective natalizumab pregnancy reg-
istry contained 355 cases and their outcomes. There were 
316 live births, 29 of which were reported to have birth 
defects. Sixteen of the 29 were considered major defects. 
The rate of defects corresponds to the ones reported in 
other pregnancy registries involving MS patients. There 
is no evidence of a specific pattern of birth defects with 
this drug.
Cases from published literature reported transient mild 
to moderate thrombocytopenia and anaemia observed 
in infants born to women exposed to natalizumab in 
their third trimester of pregnancy. Therefore, it is recom-
mended that newborns of women exposed to this drug 
during the third trimester of pregnancy are screened for 
potential haematological complications.
Breast-feeding should be discon-





mended for 12 months after 
last dose
There is a limited amount of data from the use of ocreli-
zumab in pregnant women. Postponing vaccination with 
live or live-attenuated vaccines should be considered for 
neonates and infants born to mothers who have been 
exposed to ocrelizumab in utero. No B cell count data 
have been collected in neonates and infants exposed to 
ocrelizumab and the potential duration of B-cell deple-
tion in neonates and infants is unknown. 
Animal studies (embryo-fetal toxicity) do not indicate 
teratogenic effects. B-cell depletion in utero was de-
tected. Reproductive toxicity was observed in pre- and 
post-natal development studies.
Ocrelizumab should be avoided during pregnancy unless 
the potential benefit to the mother outweighs the poten-
tial risk to the foetus.






nation to achieve <0.02 mg/L 
if pregnancy occurs/prior to 
stopping contraceptive use
Studies in animals have shown reproductive toxi-city.
Teriflunomide may cause serious birth defects when 
administered during pregnancy. Teriflunomide is contra-
indicated in pregnancy.
Teriflunomide is contraindicated 
during breast-feeding
0.0006% of the maternal dose of interferon beta-1a in breast 
milk. In addition, interferon beta-1a is poorly absorbed 
when taken orally, so it is not expected to get into the blood-
stream of a newborn when breastfeeding [38, 39]. Latest EU 
label permit to take interferon beta-1a during breastfeeding 
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Conclusions
Perceptions regarding pregnancy in women with MS 
and risks of DMD treatment are changing. Emerging data 
will continue to inform practical and evidence-based gui-
dance for pregnancy planning in MS. Having MS should not 
in itself limit family planning.
The possibility of pregnancy should be considered when 
prescribing DMDs to all women of childbearing age. It is 
important to provide a framework to discuss concerns re-
garding pregnancy and MS and to consider uncertainty 
about long-term disease activity.
Treatment with DMDs should not be delayed. First-line 
injectable treatments, such as glatiramer acetate and beta 
interferon, may be continued during pregnancy. In patients 
with high disease activity pulsed immune reconstitution 
therapy can be considered before pregnancy, which is not 
recommended for 4 months following alemtuzumab and 
for 6 months following treatment with cladribine. After this 
time-frame there are no contraindications.
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period. Whereas in the case of glatiramer acetate prepara-
tions, a choice should be made between lactation and their 
intake, weighing the benefits for the child from breast feed-
ing and the benefits of the mother from treatment. 
There`s a lack of treatment options for women with 
persistent high disease activity who do not wish to delay 
pregnancy. However, with the advent of pulsed immune re-
constitution therapies represented with alemtuzumab and 
cladribine there`s additional opportunity for family plan-
ning. Whereas drugs used for maintenance or escalation 
therapy do not maintain their beneficial effect after ces-
sation of therapy, these new highly effective therapies can 
show prolonged treatment effects after a short treatment 
course [40]. Despite that mitoxantrone could be used not 
only as induction, but as pulsed immune reconstitution 
therapy, there are no data supporting its use as pulsed im-
mune reconstitution therapy. Moreover, due to frequent se-
vere adverse events, mitoxantrone is not recommended for 
routine use in patients with RRMS [40]. 
It is possible to become pregnant and breast-feed after 
the last administration of the drug in 4 months for alemtu-
zumab or in 6 months for cladribine.
Long-term remission is seen in most of patients after 
treatment with alemtuzumab and cladribine. After one full 
course of alemtuzumab 58.0–68.5% of patients did not need 
additional cycles for 5 years. In the 5-year extension of the 
CARE-MS I study 31.5% of the patients received additional 
alemtuzumab cycles: 22.1% received one additional cycle, 
8.0% two additional cycles and 1.4% received three addi-
tional cycles [40].
After cladribine 3.5 mg/kg in the 2-year randomized 
placebo-controlled study, 75.1% of patients remained re-
lapse-free in years 3 and 4 without further treatment. Pri-
mary interim analysis of CLASSIC-MS study which is the 
median 10 years’ follow-up of patients from the cladribine 
tablets clinical development program showed that 73.5% of 
patients did not require further DMD treatment until ≥4 
years after last dose of cladribine tablets [41].
The main safety risks of pulsed immune reconstitution 
therapy include reactivation of latent infections such as tu-
berculosis, and risk of herpes zoster which is associated with 
severe lymphopenia. As a reflection of the mechanism of ac-
tion of cladribine, lymphopenia was more frequent in the 
cladribine groups (combined cladribine group 27% versus 
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